Apr 01, 2021 / 12:30PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks. And thanks, everyone, for continuing on and joining this discussion. I'm happy to be here with Richard Pops, Chairman and CEO of Alkermes, who I've done a number of panels with over the years. And just coming out of your Investor Day, it sounds like we've got a lot to talk about.
So Richard, I don't know if you want to just quickly set the stage and talk about some of your recent pipeline updates, the ALKS 3831 NDA and the status there, and then we can get into specifics. How does that sound?
Richard F. Pops - Alkermes plc - Chairman & CEO
That's good. Well, first of all, it's good to see you, Paul. I'm glad you're well. This is a really important time for Alkermes, and I think that last week was an important moment. And we had taken -- there've been a number of years before we -- a number of years since we've had an Investor Day, and we were waiting for the maturation of certain things in the
Alkermes Plc at Stifel CNS Day Transcript
Apr 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers